82 related articles for article (PubMed ID: 22356656)
1. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutières syndrome.
Tüngler V; Silver RM; Walkenhorst H; Günther C; Lee-Kirsch MA
Br J Dermatol; 2012 Jul; 167(1):212-4. PubMed ID: 22356656
[No Abstract] [Full Text] [Related]
2. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome.
Rice G; Newman WG; Dean J; Patrick T; Parmar R; Flintoff K; Robins P; Harvey S; Hollis T; O'Hara A; Herrick AL; Bowden AP; Perrino FW; Lindahl T; Barnes DE; Crow YJ
Am J Hum Genet; 2007 Apr; 80(4):811-5. PubMed ID: 17357087
[TBL] [Abstract][Full Text] [Related]
3. Systematic analysis of genotype-phenotype variability in siblings with Aicardi Goutières Syndrome (AGS).
de Barcelos IP; Woidill S; Gavazzi F; Modesti NB; Sevagamoorthy A; Vanderver A; Adang L
Mol Genet Metab; 2024 May; 142(1):108346. PubMed ID: 38368708
[TBL] [Abstract][Full Text] [Related]
4. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.
Rice GI; Forte GM; Szynkiewicz M; Chase DS; Aeby A; Abdel-Hamid MS; Ackroyd S; Allcock R; Bailey KM; Balottin U; Barnerias C; Bernard G; Bodemer C; Botella MP; Cereda C; Chandler KE; Dabydeen L; Dale RC; De Laet C; De Goede CG; Del Toro M; Effat L; Enamorado NN; Fazzi E; Gener B; Haldre M; Lin JP; Livingston JH; Lourenco CM; Marques W; Oades P; Peterson P; Rasmussen M; Roubertie A; Schmidt JL; Shalev SA; Simon R; Spiegel R; Swoboda KJ; Temtamy SA; Vassallo G; Vilain CN; Vogt J; Wermenbol V; Whitehouse WP; Soler D; Olivieri I; Orcesi S; Aglan MS; Zaki MS; Abdel-Salam GM; Vanderver A; Kisand K; Rozenberg F; Lebon P; Crow YJ
Lancet Neurol; 2013 Dec; 12(12):1159-69. PubMed ID: 24183309
[TBL] [Abstract][Full Text] [Related]
5. Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots.
Armangue T; Orsini JJ; Takanohashi A; Gavazzi F; Conant A; Ulrick N; Morrissey MA; Nahhas N; Helman G; Gordish-Dressman H; Orcesi S; Tonduti D; Stutterd C; van Haren K; Toro C; Iglesias AD; van der Knaap MS; Goldbach Mansky R; Moser AB; Jones RO; Vanderver A
Mol Genet Metab; 2017 Nov; 122(3):134-139. PubMed ID: 28739201
[TBL] [Abstract][Full Text] [Related]
6. Measuring TREX1 and TREX2 exonuclease activities.
Hemphill WO; Perrino FW
Methods Enzymol; 2019; 625():109-133. PubMed ID: 31455522
[TBL] [Abstract][Full Text] [Related]
7. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.
Lehtinen DA; Harvey S; Mulcahy MJ; Hollis T; Perrino FW
J Biol Chem; 2008 Nov; 283(46):31649-56. PubMed ID: 18805785
[TBL] [Abstract][Full Text] [Related]
8. New roles for the major human 3'-5' exonuclease TREX1 in human disease.
Kavanagh D; Spitzer D; Kothari PH; Shaikh A; Liszewski MK; Richards A; Atkinson JP
Cell Cycle; 2008 Jun; 7(12):1718-25. PubMed ID: 18583934
[TBL] [Abstract][Full Text] [Related]
9. TREX1 is required for microglial cholesterol homeostasis and oligodendrocyte terminal differentiation in human neural assembloids.
Goldberg G; Coelho L; Mo G; Adang LA; Patne M; Chen Z; Garcia-Bassets I; Mesci P; Muotri AR
Mol Psychiatry; 2024 Mar; 29(3):566-579. PubMed ID: 38129659
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Fine Motor and Visual Motor Skills in Aicardi-Goutières Syndrome.
Cusack SV; Gavazzi F; de Barcelos IP; Modesti NB; Woidill S; Formanowski B; DeMauro SB; Lorch S; Vincent A; Jawad AF; Estilow T; Glanzman AM; Vanderver A; Adang LA
J Child Neurol; 2024 Mar; 39(3-4):147-154. PubMed ID: 38532733
[TBL] [Abstract][Full Text] [Related]
11. Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome.
Dell'Isola GB; Dini G; Culpepper KL; Portwood KE; Ferrara P; Di Cara G; Verrotti A; Lodolo M
World J Pediatr; 2023 Jul; 19(7):635-643. PubMed ID: 36650407
[TBL] [Abstract][Full Text] [Related]
12. Type I Interferonopathies: A Clinical Review.
Wang CS
Rheum Dis Clin North Am; 2023 Nov; 49(4):741-756. PubMed ID: 37821193
[TBL] [Abstract][Full Text] [Related]
13. Aicardi-Goutières Syndrome (AGS) Presenting with Psoriasis.
Wander A; Meena AK; Khan I; Jauhari P; Chakraborty B; Gulati S
Indian J Pediatr; 2024 Apr; 91(4):409. PubMed ID: 37943465
[No Abstract] [Full Text] [Related]
14. Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutières syndrome.
Vancura J; Boyd NK; Vogel BN; Nagesh D; Ho E; Santoro JD
J Neurol; 2024 Feb; 271(2):1019-1022. PubMed ID: 37855872
[No Abstract] [Full Text] [Related]
15. TREX1 cytosolic DNA degradation correlates with autoimmune disease and cancer immunity.
Fang L; Ying S; Xu X; Wu D
Clin Exp Immunol; 2023 Mar; 211(3):193-207. PubMed ID: 36745566
[TBL] [Abstract][Full Text] [Related]
16. Familial chilblain lupus with TREX1 mutation and cerebrovascular disease.
Nohara T; Yanagi T; Yabe I; Ota N; Kanazawa N; Ujiie H; Kosumi H; Mai Y; Shimizu H
Lancet Rheumatol; 2020 Nov; 2(11):e724. PubMed ID: 38279366
[No Abstract] [Full Text] [Related]
17. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1).
Günther C; Berndt N; Wolf C; Lee-Kirsch MA
JAMA Dermatol; 2015 Apr; 151(4):426-31. PubMed ID: 25517357
[TBL] [Abstract][Full Text] [Related]
18. A nationwide survey of Aicardi-Goutières syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study.
Abe J; Nakamura K; Nishikomori R; Kato M; Mitsuiki N; Izawa K; Awaya T; Kawai T; Yasumi T; Toyoshima I; Hasegawa K; Ohshima Y; Hiragi T; Sasahara Y; Suzuki Y; Kikuchi M; Osaka H; Ohya T; Ninomiya S; Fujikawa S; Akasaka M; Iwata N; Kawakita A; Funatsuka M; Shintaku H; Ohara O; Ichinose H; Heike T
Rheumatology (Oxford); 2014 Mar; 53(3):448-58. PubMed ID: 24300241
[TBL] [Abstract][Full Text] [Related]
19. Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains genome integrity through exonuclease-independent ORF1p depletion.
Li P; Du J; Goodier JL; Hou J; Kang J; Kazazian HH; Zhao K; Yu XF
Nucleic Acids Res; 2017 May; 45(8):4619-4631. PubMed ID: 28334850
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
